Tarsus director settles 2,954 RSUs into shares

Tarsus Pharmaceuticals director Katherine Goodrich acquired common shares through an equity award vesting, not an open-market purchase.

Rhea-AI Filing Summary

Tarsus Pharmaceuticals director Katherine Goodrich acquired common shares through an equity award vesting, not an open-market purchase. On June 12, 2026, 2,954 Restricted Stock Units (RSUs) settled into 2,954 shares of Tarsus common stock at a price of $0.00 per share, reflecting a compensation-related equity grant.

Following this RSU settlement, Goodrich directly owns 5,187 shares of Tarsus common stock. No shares were reported as sold or disposed of in this filing, and no tax-withholding or gifting transactions were disclosed.

Insider Trade Summary

2,954 shares exercised/converted

Exercise 2 txns

Insider Goodrich Katherine

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	2,954	$0.00	$0.00
Exercise	Common Stock	2,954	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 0 contracts (Direct); Common Stock — 5,187 shares (Direct)

Footnotes (3)

1. F1. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
2. F2. Each RSU represents a contingent right to receive one share of the Company's common stock.
3. F3. RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Key Figures

RSUs settled: 2,954 units Common shares acquired: 2,954 shares Post-transaction holdings: 5,187 shares +2 more

5 metrics

RSUs settled 2,954 units Restricted Stock Units converting into common stock on June 12, 2026

Common shares acquired 2,954 shares Shares issued upon RSU settlement at $0.00 per share

Post-transaction holdings 5,187 shares Total Tarsus common stock directly owned after RSU conversion

Exercise price $0.00 per share Stated transaction price for RSU conversion to common stock

Transactions classified as acquisitions 2 transactions Both RSU derivative and common stock entries marked as acquire

Key Terms

Restricted Stock Units, contingent right, non-employee director, annual meeting of stockholders, +1 more

5 terms

Restricted Stock Units financial

"The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs")."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Company's common stock."

non-employee director financial

"RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director."

annual meeting of stockholders financial

"RSUs granted ... as of the Company's 2025 annual meeting of stockholders."

vest in full financial

"The RSUs will vest in full on the one-year anniversary of the date of grant."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Tarsus Pharmaceuticals (TARS) report for Katherine Goodrich?

Tarsus Pharmaceuticals reported that director Katherine Goodrich acquired 2,954 common shares through settlement of vested RSUs. This was a compensation-related equity award conversion, with no open-market buying or selling activity disclosed in the filing.

How many Tarsus Pharmaceuticals shares does Katherine Goodrich hold after this Form 4?

After the RSU settlement, Katherine Goodrich directly holds 5,187 shares of Tarsus Pharmaceuticals common stock. The filing shows these shares as direct ownership and does not indicate any concurrent sales or transfers reducing this position.

Was the Tarsus Pharmaceuticals Form 4 transaction a stock purchase or RSU vesting?

The Form 4 reflects RSU vesting and settlement, not an open-market stock purchase. 2,954 Restricted Stock Units converted into 2,954 common shares at a stated price of $0.00 per share as part of director equity compensation.

Did Katherine Goodrich sell any Tarsus Pharmaceuticals (TARS) shares in this Form 4?

No sales were reported. The Form 4 only shows the exercise or conversion of 2,954 RSUs into common shares, with no corresponding sale, tax-withholding disposition, or gift transactions disclosed for the same date.

What are Restricted Stock Units (RSUs) in the Tarsus Pharmaceuticals filing?

In this filing, each RSU represents a contingent right to receive one share of Tarsus common stock. 2,954 RSUs vested and settled into 2,954 shares, reflecting non-cash equity compensation for service as a non-employee director.

When were the RSUs related to this Tarsus Pharmaceuticals Form 4 originally granted?

The RSUs were granted on June 12, 2025, in connection with Katherine Goodrich’s service as a non-employee director as of the 2025 annual meeting. They vest in full on the one-year anniversary of the grant date, subject to continuous service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/16/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Goodrich Katherine

(Last) (First) (Middle)

C/O TARSUS PHARMACEUTICALS, INC.

15440 LAGUNA CANYON ROAD, SUITE 160

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/12/2026		M(1)		2,954	A	(1)	5,187	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	06/12/2026		M			2,954	(3)	(3)	Common Stock	2,954	$0	0	D

Explanation of Responses:

1. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

2. Each RSU represents a contingent right to receive one share of the Company's common stock.

3. RSUs granted on June 12, 2025, in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Remarks:

	/s/ Jeffrey Farrow, Attorney-in-Fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)